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ABSTRACT
A common drug repositioning strategy is the re-
application of an existing drug to address alterna-
tive targets. A crucial aspect to enable such repur-
posing is that the drug’s binding site on the origi-
nal target is similar to that on the alternative target.
Based on the assumption that proteins with simi-
lar binding sites may bind to similar drugs, the 3D
substructure similarity data can be used to identify
similar sites in other proteins that are not known tar-
gets. The Drug ReposER (DRug REPOSitioning Ex-
ploration Resource) web server is designed to iden-
tify potential targets for drug repurposing based on
sub-structural similarity to the binding interfaces of
known drug binding sites. The application has pre-
computed amino acid arrangements from protein
structures in the Protein Data Bank that are similar
to the 3D arrangements of known drug binding sites
thus allowing users to explore them as alternative tar-
gets. Users can annotate new structures for sites that
are similarly arranged to the residues found in known
drug binding interfaces. The search results are pre-
sented as mappings of matched sidechain superpo-
sitions. The results of the searches can be visualized
using an integrated NGL viewer. The Drug ReposER
server has no access restrictions and is available at
http://mfrlab.org/drugreposer/.
INTRODUCTION
The introduction of new approved drugs to the market is
both a time consuming and costly endeavour. One approach
to circumvent the lengthy development processes and to sig-
nificantly reduce the costs is to repurpose drugs that are al-
ready in use for other indications (1). Despite numerous ef-
forts aimed at the discovery of new drugs, their success rate
is rather nominal with the majority of the compounds never
reaching clinical trials or failing at the final clinical trials
stages (2). The stringent considerations that need to be met
for the approval of new therapeutic compounds has resulted
in increased interest being directed at the repurposing or
repositioning of already approved drugs (3). Both academia
and industry have worked together towards proposing new
indications for existing drugs with proven track records that
would in turn allow for better cost optimization compared
to developing and testing new compounds (4).
Thalidomide and sildenafil are two examples of success-
ful drug repurposing initiatives. Thalidomide had been ap-
proved by U.S. Food and Drug Administration (FDA) in
1950s and primarily used for morning sickness during the
first trimester of pregnancy. It was later withdrawn in 1961
due to teratogenic effects (5) but was recently reintroduced
for other indications including multiple myeloma (6) and
leprosy (7). Sildenafil, which targets cyclic GMP phospho-
diesterase 5 (PDE5), had first been discovered as an anti-
hypertensive due to its vasodilatory effects and was success-
fully repurposed for erectile dysfunction and pulmonary ar-
terial hypertension (8). However, in the case of sildenafil,
the repurposing efforts have focused on different indications
that are treatable by targeting PDE-5 (9) and therefore does
not involve an alternative target for the drug.
However, drug repositioning can also happen for cases
where an approved compound may have an alternative tar-
get. The mode of interaction and atomic level details by
which a drug exerts its effects are important aspects in un-
derstanding its therapeutic mechanism. Knowledge on the
ability of a drug molecule to bind to alternate targets and
the role of that protein in a particular disease mechanism
or pathway is also crucial when investigating the potential
off-targets and adverse effects (10) of the candidate. As a
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result of this understanding, there are numerous entries in
the ProteinData Bank (11) of target proteins bound to drug
compounds.
The availability of these protein drug complexes allows
information about the amino acid residues that are inter-
acting with the drug compounds to be extracted thus mak-
ing it possible to know the specific 3D arrangements of
the amino acids partaking in the interaction. Previously,
computer programs such as ASSAM, SPRITE (12) and
IMAAAGINE (13) have shown that approaches using com-
parisons of the amino acid side chain arrangements have
certain advantages over approaches that only consider the
carbon backbone positions. In the context of protein–drug
complexes, it is expected that the majority of the interac-
tions with the drugs will involve the side chain. By modify-
ing such search programs, it is therefore possible to identify
other amino acid 3D arrangements that are similar to those
known to be involved in the drug interactions.
Proteins containing amino acid arrangements that are
similar to that of a known drug binding site may potentially
bind to the same drug compound or a similarly structured
molecule, and thus such a site can be proposed as a target for
drug repositioning. The occurrences of similarly arranged
amino acid residues among proteins of different folds and
functions are not expected to be as common as between ho-
mologs. When such similarities are found to be present in
non-homologous proteins, it can be a useful starting point
to find unrelated targets for existing drugs and thus allow-
ing for different targets to be explored for an existing com-
pound. In essence, large-scale analysis of such binding site
similarities has the potential to yield alternative targets that
can pave the way for drug repositioning and also investiga-
tions into toxicity or side effects of known drugs.
Currently available resources for drug discovery and drug re-
purposing
There are various databases currently available for the an-
notation of drugs, targets and drug–target interactions,
such as DrugBank (14) and Therapeutic Target Database
(TTD) (15). These databases provide access to candidate
compounds with comprehensive information attached and
are thus useful for drug design and development. These re-
sources are based on literature analysis of experimental vali-
dation and clinical data, as well as information consolidated
from other curated databases and regulatory agencies. Sev-
eral drug repurposing databases have also been developed
to facilitate the exploration of approved drugs currently un-
dergoing clinical trials for new indications. For example, Re-
purposeDB compiles a collection of drugs, drug targets, dis-
eases, and reports of successful drug repositioning activities
(16) andRepoDB stores approved and failed drugs from ex-
periments and clinical trials (17). These databases provide
benchmarks and valuable insights indicative of the success
rate of repurposing target prediction from computational
predictions up to the point of commercial availability of the
drug.
A number of freely available web servers offer users the
ability to explore repurposing opportunities by providing ei-
ther access to an interface for the virtual screening of small
molecules (18), access to a searching function for similar
compounds (17–19), or access to a search function for simi-
lar binding sites (20,21). Local structural similarity searches
for drug binding sites of proteins in the PDB had been im-
plemented by various web servers with varying degrees of
success in exploring the potential for repurposing approved
drugs (22–24).
The Drug ReposER (DRug REPOSitioning Exploration
Resource) web server facilitates the searching of potential
alternative targets for known compounds by comparing the
similarities of the 3D amino acid arrangements in known
targets to other structures available in the PDB.While there
are several other databases and web servers that carry the
‘drug repurposing’ or ‘drug repositioning’ label, none of
them utilize a structural comparison approach of finding
similar binding sites as a means to identify and explore po-
tential targets for drug repositioning. For example, other
available drug repurposing resources only provide informa-
tion on the existing status of drugs for repurposing or serve
as a repository of repurposed drugs and their targets but do
not allow users to actively explore new targets for reposi-
tioning or allow investigations into optimizing or modify-
ing existing compounds to interact with a new target with a
structural context.
METHODOLOGY
Datasets: Known binding sites for approved drugs
The list of approved drugs used in Drug ReposER were ex-
tracted from the ‘Drug and Drug Target Mapping’ inter-
face in the RCSB PDB database (11); 3203 protein struc-
tures bound to 512 selected drug molecules were used to ex-
tract patterns containing residues that were defined as bind-
ing because there were within 4.0 A˚ or less distance from
the atoms of a molecule that had been classified as a drug.
The patterns include those from 66 PDB structures of mem-
brane proteins that are known to bind to various drugs.
These binding site patterns and their annotations have been
made available via theDrugReposERweb server. The bind-
ing site patterns were also compiled into a database of 3D
patterns that allow users to identify the presence of similarly
arranged amino acids in a query protein structure using a
modified version of the SPRITE search engine (12).
Similarly arranged patterns of amino acids predicted to bind
to approved drugs
The 3D patterns of known drug binding sites were used
as queries to search the PDB for other proteins that con-
tained similarly arranged sites using the ASSAM computer
program previously described in Nadzirin et al. (12). The
program compares each binding site pattern against a non-
redundant PDB dataset at a 90% sequence identity cut-off.
The searches resulted in more than 100 000 amino acid
3D arrangements that had varying degrees of similarity to
amino acid tertiary arrangements that formed the bind-
ing sites to known drug compounds. From this total, 689
PDB structures of membrane proteins were found to con-
tain amino acid tertiary arrangements that are similar to
known drug binding sites. This dataset is searchable via
the Drug ReposER web interface. No further filtering was
done on the dataset to reduce its number. As a result, the
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dataset will also contain examples of matches to a known
drug binding site for proteins that are not obvious drug tar-
gets. We feel that this provides the user with options to look
for homologs for which structures are not available in other
organisms such as humans. It is therefore the user’s prerog-
ative to provide the context to explore the drug reposition-
ing strategy. Users can however carry out their own filtering
such as by setting parameters for the number of matches or
the superposed 3D similarity of the sites asmeasured in root
mean square deviation (rmsd) values.
Web development and infrastructure
The corresponding database used in the web server was gen-
erated using MySQL (version 5.1.44) consisting of two in-
terconnected tables, while all web interfaces and results page
were developed using PHP (version 5.3.1) and Python (ver-
sion 2.7). The Drug ReposER server is hosted on a Linux
server (CentOS) physically located at theMalaysia Genome
Institute, Malaysia. The server is equipped with dual In-
tel Xeon processors and 64 GB of memory. The Drug Re-
posER web application was successfully tested on various
platforms including Windows and Mac OS.
The Drug ReposER user interface
The Drug ReposER web server consists of three search op-
tions: (i) searching for amino acid 3D arrangements that are
similarly postured to known drug binding sites: (ii) search-
ing for 3D structure information of binding sites for ap-
proved drugs as retrieved from protein-drug complexes in
the PDB; and; (iii) searching a user provided structure for
the presence of sites that are similarly arranged to those
of known drug binding sites (Supplementary Figure S1).
The integrated SPRITE search engine had been reported by
Nadzirin et al. (12) but was modified with a specific search
database of known drug binding sites for use in the Drug
ReposER application.
Search for amino acid arrangements similar to known drug
binding sites in PDB structures
The Drug ReposER application can be used to determine
whether a PDBprotein structure contains 3D arrangements
of amino acids that are similar to that for known drug bind-
ing sites. Users can opt to execute this type of search by
providing a PDB ID or PDB ligand ID input that returns
a results page with an NGL viewer showing the 3D struc-
ture of the query protein or ligand, and a list of similar
amino acid arrangements that matches the query term (Fig-
ure 1A). The interface searches the query term against a
database of 3D amino acid arrangements similar to known
drug binding sites, obtained from a non-redundant PDB
dataset (Supplementary Figure S1). If the query PDB ID is
available in the database, the interface returns all 3D amino
acid arrangements (query pattern) found in query protein
that are similarly arranged to that of known drug binding
sites (hit pattern) and presented together with information
regarding any nearby heteroatoms, such as bound anno-
tated drugs, experimental drugs, or metal ions that are at
the vicinity of the query patterns within a distance cut-off
of 4.0A˚. The presence of nearby heteroatoms can also be
searched through the ligand based search by providing a
Ligand ID query. Users can also opt to view superpositions
of amino acid arrangements in the queries and those from
the references using the NGL viewer by clicking the ‘View’
link available on the last column of the table. Meanwhile,
clicking on the DrReposER ID on the first column opens
the corresponding results page for the selected binding site.
Search for drug binding interfaces from protein-drug com-
plexes
The interface also allows users to search for known binding
sites to approved drugs derived from the PDB, by providing
a query term for searching the data set of binding sites for
approved drugs. A query of PDB ID, ligand ID, drug name
or DrugBank ID returns a list of binding interfaces match-
ing the query term in an NGL viewer (25) showing the 3D
structure of the query protein or ligand molecule (Figure
1B). Although there are some similarities of this feature to
other services available, they were also integrated in order to
allow for users to contain their analysis within the Drug Re-
posER interface asmuch as possible without needing to exit
into other resources. There are two search options available
for this feature; one produces the structural information re-
garding the protein and the other presents the drug indi-
cation as annotated from the DrugBank for the given drug
molecule (Figure 1B). Users may also search using keyword
queries under different categories that include drug indi-
cation, organism, protein name and Pfam annotation (26).
Such an interrogation returns a list of binding sites match-
ing the keywords. Clicking a DrReposER ID on the first
column returns a results page for the individual data asso-
ciated with that ID that describes the binding site and a list-
ing for a set of similarly arranged sites in other proteins,
along with the matched protein structure’s RMSD value
from the superposition, the Z-score from fold comparison
using DaliLite (27) and sequence identity values from se-
quence comparison using MUSCLE program (28). Users
can then click on the ‘View’ link on the last column to visu-
alize the superposed patterns and compare both the query
and the matches.
Search for residue arrangements in query structure similar to
known drug binding sites
In cases when the structure of interest is not currently avail-
able in the PDB or the dataset used, the user can up-
load the coordinates of their own protein structure. This
is another Drug ReposER specific feature that is unavail-
able at other similarly intended services. After submitting
the query, the SPRITE program searches the query pro-
tein against a database of known drug binding sites (12).
A typical SPRITE search, although dependent on the cur-
rent server load and size of the input structure, would typi-
cally approximately twominutes to execute. Once the search
is completed, users can select to view results for the left-
handed and right-handed superposition (12) of matched
patterns of amino acids in the query structure (query pat-
tern) against known drug binding sites (hit pattern) (Figure
1C).
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Figure 1. The Drug ReposER search interfaces. (A) Searching for amino acid arrangements in PDB structures that are similar to known drug binding
sites. (B) Searching for drug binding interfaces in protein–drug complexes. (C) Searching for residue arrangements in query structure similar to a known
drug binding site.
Visualization of structures and superpositions in the NGL
viewer
The Drug ReposER web server integrates the NGL viewer
(25) for visualization of 3D structures and for visual in-
spection of the superposed patterns of amino acids. The su-
perposed binding residues can be viewed upon clicking the
‘View’ link in the ‘View’ column. Binding residues and drug
molecules from the query protein are shown in grey and
magenta respectively, while the matched pattern is shown
in green. The superposition of query and matched ligands
can be viewed upon clicking the ‘Ligand on/off’ button,
while the superposition of their backbone structures can be
viewed by clicking the ‘Backbone on/off’ button. Various
pre-set display options are also provided, including chang-
ing the background colour, the depiction of ligand bind-
ing pockets, and indication of side chain atoms (Figure 2).
Users are also given the options to download screenshots of
the viewer window.
CASE STUDY: AN EXAMPLE PROCESS FOR DISCOV-
ERING POTENTIAL TARGETS FOR DRUG REPOSI-
TIONING
Repositioning of acetylcysteine for tuberculosis
In this case study, we avoid a direct example that pro-
poses an alternative target for drug repositioning. We in-
stead demonstrate the utility of the application in propos-
ing possible mechanisms brought about by repositioning
of a known drug that is also supported by clinical tri-
als data. Acetylcysteine (PDB ligand: SC2) is an approved
small molecule mucolytic agent that acts by reducing mu-
cus thickness (29), and is also used for the management of
acetaminophen poisoning by maintaining the levels of glu-
tathione in the liver (30). The PDB contains several pro-
tein structures that are in complex with acetylcysteine. One
example, human Ficolin-2 (PDBID: 2j1g) (31), is a protein
that recognizes various molecular patterns from pathogen
surfaces, such as acetylated carbohydrates and other acety-
lated compounds and is thus important for the innate im-
mune system (31). Acetylcysteine is known to inhibit the
binding of Ficolin-2 to Streptococcus pneumoniae (32). L-
ficolin had been reported to block the infection ofMycobac-
terium tuberculosis H37Rv in lung cells by binding to the
glycolipid region of the bacterial surface (33).
To explore potential new targets for acetylcysteine, we
searched for amino acid arrangements that are similar to
the acetylcysteine binding site in Ficolin-2 (Figure 3A) us-
ing the structure 2j1g as a query. We then selected the en-
try DrReposER entry 2J1G F SC2F1290’ for further anal-
ysis. One of the similarly arranged amino acid patterns is
a five residue pattern in sulfate ester dioxygenase Rv3406
from M. tuberculosis H37Rv (PDBID: 4cvy) (34) (Figure
3B). The Rv3406 protein does not share any detectable se-
quence or structural similarity to human Ficolin-2, but the
report from Luo and colleagues clearly indicates the role
of Ficolin-2 in defence against M. tuberculosis H37Rv in-
fection (33). Molecular docking using the SwissDock web
server (35) resulted in several conformations for Rv3406-
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Figure 2. Multiple screenshots of the embedded NGL viewer in the Drug ReposER server. (A) Binding site for acarbose from alpha amylase is represented
in licorice, while the protein structure can be viewed in backbone representation. (B) Binding pocket for acarbose (ACR) from alpha amylase (1mxd) is
shown in surface representation and coloured green. (C) Superposed patterns of amino acids from the known binding site for acarbose (1mxd, grey) and
similarly arranged pattern of amino acids from glutathione reductase (2hqm, green) bound to flavin adenine dinucleotide (FAD); superposed ligands can
also be viewed; ACR is coloured in purple and FAD is coloured in white. (D) Superposed protein structures of 1mxd (grey) and 2hqm (green) are shown
in backbone representation.
acetylcysteine binding similarly as presented from the ar-
rangement similarity retrieved by the Drug ReposER server
(Figure 3C and D), thus suggesting the Rv3406 protein can
serve as an alternative target for acetylcysteine.
Amaral and colleagues had proven the anti-
mycobacterial activity of N-acetylcysteine in M. tu-
berculosis through in-vitro and in-vivo experiments that
revealed a reduction of oxidation stress and mycobacterial
loads, respectively (36). Due to its antioxidant effects, the
ClinicalTrials.gov server (37) also reported an ongoing
phase II randomized clinical trial to test the potential role
of acetylcysteine as an adjuvant therapy for tuberculosis
(ClinicalTrials.gov identifier: NCT03281226), thus suggest-
ing the potential role of acetylcysteine as a tuberculosis
drug. Analysis with Drug ReposER can put into context
the mechanisms that may be in effect as observed for the
clinical trials. As a mucus reducing agent, it is expected that
acetylcysteine would be used for patients with tuberculosis.
However, acetylcysteine can also target Ficolin-2 and
inadvertently affect the innate immune system response.
Despite this fact, the clinical trials revealed that acetylcys-
teine may have other targets that negates that function and
is thus able to produce a net anti-mycobacterial effect.
SUMMARY
The Drug ReposER server provides comprehensive infor-
mation of known drug binding sites that are deployed
to identify potentially alternative targets for drug reposi-
tioning. The use of the ASSAM and SPRITE computer
programs provide a high-throughput but fast whole PDB
search capacity that has not been previously explored by
other resources. Furthermore, many previous drug repur-
posing efforts have concentrated on one compound of inter-
est as a starting point to identify other indications for which
it may have therapeutic effects. The outputs provided by the
DrugReposER server can facilitate a larger scale analysis of
protein-drug interactions that can guide experimental val-
idation of potentially new protein-drug interactions that is
not limited to exploring a single compound of interest as
a starting point. The Drug ReposER application is there-
fore useful for the identification of potentially new targets
for existing drugs and/or the rational modification of exist-
ing compounds to be fitted to new targets that have local or
substructure similarities to that of an existing target site, as
well as allowing for investigations into possible toxicity and
off-target interactions.
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Figure 3. Results of molecular docking prediction performed by SwissDock. (A) Binding site for acetylcysteine found in human Ficolin-2 (PDBID: 2j1g).
Binding site is coloured blue with surface representation. (B) Superposition of binding site for acetylcysteine in human Ficolin-2 (PDBID: 2j1g, light blue
colour) to five-residue pattern from Rv3406 protein predicted from the server (PDBID: 4cvy, orange color). (C) Model of acetylcysteine against Rv3406
protein fromMycobacterium tuberculosis, with G score of −6.34 kcal/mol. (D) Predicted binding site for acetylcysteine from Drug ReposER web server
is indicated in orange and the conformation of acetylcysteine predicted from the SwissDock is coloured in light blue.
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